Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline

AIMS: Perhexiline is an antianginal agent that displays both saturable and polymorphic metabolism via CYP2D6. The aim of this study was to determine whether perhexiline produces clinically significant inhibition of CYP2D6-catalysed metabolism in angina patients. METHODS: The effects of perhexiline o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Davies, Benjamin J L, Coller, Janet K, James, Heather M, Gillis, David, Somogyi, Andrew A, Horowitz, John D, Morris, Raymond G, Sallustio, Benedetta C
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Science Inc 2004
Assuntos:
Drug Interactions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1884464/
https://ncbi.nlm.nih.gov/pubmed/15025744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.2003.02033.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados